Research Article 
The informatics core of the Alzheimer’s Disease Neuroimaging Initiative
Arthur W. Toga and Karen L. Crawford
Alzheimer`s & Dementia, 2010, 6(3), 247-256. DOI: 10.1016/j.jalz.2010.03.001
Abstract
The Alzheimer’s Diseases Neuroimaging Initiative project has brought together geographically distributed investigators, each collecting data on the progression of Alzheimer’s disease. The quantity and diversity of the imaging, clinical, cognitive, biochemical, and genetic data acquired and generated throughout the study necessitated sophisticated informatics systems to organize, manage, and disseminate data and results. We describe, here, a successful and comprehensive system that provides powerful mechanisms for processing, integrating, and disseminating these data not only to support the research needs of the investigators who make up the Alzheimer’s Diseases Neuroimaging Initiative cores, but also to provide widespread data access to the greater scientific community for the study of Alzheimer’s Disease.
ASCI-ID: 285-24
Similar Articles
Update on the Magnetic Resonance Imaging core of the Alzheimer’s Disease Neuroimaging Initiative
Alzheimer`s & Dementia, 2010, 6(3), 212-220. DOI: 10.1016/j.jalz.2010.03.004
Clinical core of the Alzheimer’s disease neuroimaging initiative: Progress and plansAlzheimer`s & Dementia, 2010, 6(3), 239-246. DOI: 10.1016/j.jalz.2010.03.006
The Alzheimer’s Disease Neuroimaging Initiative: Progress report and future plansAlzheimer`s & Dementia, 2010, 6(3), 202-211. DOI: 10.1016/j.jalz.2010.03.007
Alzheimer’s Disease Neuroimaging Initiative in EuropeAlzheimer`s & Dementia, 2010, 6(3), 280-285. DOI: 10.1016/j.jalz.2010.03.005
The Alzheimer’s Disease Neuroimaging Initiative: Perspectives of the Industry Scientific Advisory BoardAlzheimer`s & Dementia, 2010, 6(3), 286-290. DOI: 10.1016/j.jalz.2010.03.010
Japanese Alzheimer’s Disease Neuroimaging Initiative: Present status and futureAlzheimer`s & Dementia, 2010, 6(3), 297-299. DOI: 10.1016/j.jalz.2010.03.011
Safety profile of Alzheimer's disease populations in Alzheimer's Disease Neuroimaging Initiative and other 18-month studiesAlzheimer`s & Dementia, 2012, 8(5), 407-416. DOI: 10.1016/j.jalz.2011.05.2413
Drug treatment of Alzheimer’s disease patients leads to expression changes in peripheral blood cellsAlzheimer`s & Dementia, 2010, 6(5), 386-393. DOI: 10.1016/j.jalz.2009.12.004
White matter is altered with parental family history of Alzheimer’s diseaseAlzheimer`s & Dementia, 2010, 6(5), 394-403. DOI: 10.1016/j.jalz.2009.11.003
Influence of apolipoprotein E ε4 on rates of cognitive and functional decline in mild cognitive impairmentAlzheimer`s & Dementia, 2010, 6(5), 412-419. DOI: 10.1016/j.jalz.2009.12.003
Update on the Magnetic Resonance Imaging core of the Alzheimer’s Disease Neuroimaging InitiativeAlzheimer`s & Dementia, 2010, 6(3), 212-220. DOI: 10.1016/j.jalz.2010.03.004
Update on the biomarker core of the Alzheimer’s Disease Neuroimaging Initiative subjectsAlzheimer`s & Dementia, 2010, 6(3), 230-238. DOI: 10.1016/j.jalz.2010.03.008
Clinical core of the Alzheimer’s disease neuroimaging initiative: Progress and plansAlzheimer`s & Dementia, 2010, 6(3), 239-246. DOI: 10.1016/j.jalz.2010.03.006
The Alzheimer’s Disease Neuroimaging Initiative: Annual change in biomarkers and clinical outcomesAlzheimer`s & Dementia, 2010, 6(3), 257-264. DOI: 10.1016/j.jalz.2010.03.002
Temporal lobe functional activity and connectivity in young adult APOE ε4 carriersAlzheimer`s & Dementia, 2010, 6(4), 303-311. DOI: 10.1016/j.jalz.2009.07.003
The Alzheimer’s Disease Neuroimaging Initiative: Progress report and future plansAlzheimer`s & Dementia, 2010, 6(3), 202-211. DOI: 10.1016/j.jalz.2010.03.007
Alzheimer’s Disease Neuroimaging Initiative biomarkers as quantitative phenotypes: Genetics core aims, progress, and plansAlzheimer`s & Dementia, 2010, 6(3), 265-273. DOI: 10.1016/j.jalz.2010.03.013
Autopsy consent, brain collection, and standardized neuropathologic assessment of ADNI participants: The essential role of the Neuropathology CoreAlzheimer`s & Dementia, 2010, 6(3), 274-279. DOI: 10.1016/j.jalz.2010.03.012
Alzheimer’s Disease Neuroimaging Initiative in EuropeAlzheimer`s & Dementia, 2010, 6(3), 280-285. DOI: 10.1016/j.jalz.2010.03.005
The Alzheimer’s Disease Neuroimaging Initiative: Perspectives of the Industry Scientific Advisory BoardAlzheimer`s & Dementia, 2010, 6(3), 286-290. DOI: 10.1016/j.jalz.2010.03.010
Addressing population aging and Alzheimer’s disease through the Australian Imaging Biomarkers and Lifestyle study: Collaboration with the Alzheimer’s Disease Neuroimaging InitiativeAlzheimer`s & Dementia, 2010, 6(3), 291-296. DOI: 10.1016/j.jalz.2010.03.009
Japanese Alzheimer’s Disease Neuroimaging Initiative: Present status and futureAlzheimer`s & Dementia, 2010, 6(3), 297-299. DOI: 10.1016/j.jalz.2010.03.011
An examination of Alzheimer’s disease case definitions using Medicare claims and survey dataAlzheimer`s & Dementia, 2010, 6(4), 334-341. DOI: 10.1016/j.jalz.2009.09.001
Deliberative assessment of surrogate consent in dementia researchAlzheimer`s & Dementia, 2010, 6(4), 342-350. DOI: 10.1016/j.jalz.2009.06.001
Priorities for research consortia on Alzheimer's diseaseAlzheimer`s & Dementia, 2010, 6(4), 359-362. DOI: 10.1016/j.jalz.2010.05.2017
Improving Alzheimer‘s disease phase II clinical trialsAlzheimer`s & Dementia, 2013, 9(1), 39-49. DOI: 10.1016/j.jalz.2012.02.002